Skip to main content

Table 2 Baseline characteristics and plasma drug concentrations in males and non-pregnant females with acute ocular toxoplasmosis, both assayed in the advisory laboratory using liquid chromatography–mass spectrometry (LC–MS)

From: Sulfadiazine plasma concentrations in women with pregnancy-acquired compared to ocular toxoplasmosis under pyrimethamine and sulfadiazine therapy: a case–control study

 

OT

p-value

 

Malea

Femaleb

Age

 N

10

17

p = 0.841a

 Mean ± SD [95% CI]

26.6 ± 8.7 [20.4; 32.8]

26.1 ± 5.3 [23.6; 28.5]

 Min–max

16–48

17–35

 Median

25

27

 Percentiles (25th; 75th)

21; 29

21; 29

Days after treatment start

 N

10

17

p = 0.083b

 Mean ± SD

13 ± 2

14 ± 2

 Min–max

10–15

11–17

 Median [95% CI]d

14 [12; 14]

14 [14; 16]

 Percentiles (25th; 75th)

12; 14

13; 16

PY (µg/l)

 N

10

17

p = 0.537b

 Mean ± SD

1527 ± 667

1550 ± 1411

 Min–max

789–2630

29–6160

 Median [95% CI]d

1321 [962; 2140]

1230 [780; 1890]

 Percentiles (25th; 75th)

962; 2140

780; 1980

SA [mg/l)c

 N

10

17

p = 0.386b

 Mean ± SD

82.4 ± 47.9

69.1 ± 44.2

 Min–max

9.0–159.0

9.0–166.0

 Median [95% CI]d

82.4 [53.5; 115.0]

70.4 [52.4; 89]

 Percentiles (25th; 75th)

53.5; 115

52.4; 89.0

  1. a t-test for independent samples
  2. b Mann–Whitney U test
  3. c Detection limit set to 9.0 mg/l
  4. d 95% confidence intervals of the median were calculated using bootstrapping